The knockdown of ADAR1, in conjunction with DNMTi treatment, markedly improves cytokine production, facilitates CD8+ T cell recruitment, and decreases tumor burden in a mouse model of ovarian cancer (236). Here, ADAR is linked to ovarian carcinoma.